Sumithira Vasu, MD
Academic Title: Professor in the College of Medicine
Research Program: Leukemia and Hematologic Malignancies
About Me
More info forI am a hematologist-oncologist who specializes in treating patients with acute myeloid leukemia (AML), myelodysplastic syndromes and bone marrow transplantation. Every day, I collaborate with my colleagues at the OSUCCC – James to create targeted therapies for each patient. In addition to serving as a professor in the Division of Hematology at The Ohio State University, I also participate in grant-funded research to better understand specific cancers. As a member of the Leukemia and Hematologic Malignancies Program, my research focuses on AML and allogeneic hematopoietic stem cell transplantation. In particular, I am interested in developing pharmacologic and immunologic therapies to pre-emptively manage relapse and graft-versus-host disease following bone marrow transplantation. One of my recent studies suggests that Janus kinase 1/2 inhibitor therapy should be continued close to the start of conditioning therapy in patients who undergo allogeneic hematopoietic cell transplantation for myelofibrosis. I also serve as scientific director of the Blood and Marrow Transplantation Program and medical director of the Cell Therapy Lab, Blood and Marrow Transplantation Section. I have co-authored numerous articles in well-respected publications, including Biology of Blood and Marrow Transplantation, Leukemia & Lymphoma, Blood and Bone Marrow Transplantation. Cancer is complex, but I’m confident our research continues to bring us closer to finding a cure. It’s an honor to work at one of the nation’s premier cancer hospitals. Our collective expertise results in faster responses, fewer side effects and more hope for cancer patients everywhere.
Clinical Expertise
More info for- Myelodysplastic Syndromes
- Precursor Cell Lymphoblastic Leukemia-Lymphoma
- Acute Myeloid Leukemias
- Bone Marrow Transplantation
- Blood Cancers
Research Interests
More info for- Hematologic Neoplasms
- Hemoglobinuria, Paroxysmal
- Leukemia
- Graft vs Host Disease
- Lymphoma
- Multiple Myeloma
- Leukemia, Myeloid, Acute
Where I See Patients
More info forThe Arthur G. James Cancer Hospital and Richard J. Solove Research Institute
460 W. 10th Ave. Columbus, Ohio 43210 800-293-5066 Location InformationEducation & Training
More info forFellowship - Hematology & Oncology
- National Naval Medical Center-Bethesda-GME
10, Bethesda, MD
Internship - Internal Medicine
- St. Vincent Hospital
25 Winthrop St, Worcester, MA
Residency - Internal Medicine
- St. Vincent Hospital
25 Winthrop St, Worcester, MA
Medical School
- Thanjavur Medical College
Tamil Nadu Dr. MGR Medical University, Thanjavur 613004, Tamil Nadu
Fellowship - Blood Banking/Transfusion Medicine
- Warren G Magnuson Clinical Center/National Institu
9000 Rockville Pike, Bethesda, MD
- National Naval Medical Center-Bethesda-GME
Academic Office & Contact Information
More info forAcademic Office:
Comprehensive Cancer Center 0460
410 W 12th Ave
Columbus, Ohio 43210-1214Email:
vasu.7@osu.eduReviews
More info forPatient Satisfaction Review
The overall patient satisfaction rating is an average of all patient responses to the five questions gathered from the Outpatient Oncology survey, developed by Press Ganey Associates for use in oncology clinics across the country. On behalf of The James, Press Ganey administers the survey to patients who see our providers in an outpatient clinic office. For additional information about the patient satisfaction survey, please visit our
Patient Satisfaction Survey page The comments are submitted by patients and reflect their view and opinions. The comments are not endorsed by and do not necessarily reflect the views of The James.
Videos
More info forPublications
More info forOctober 12, 2024Combination ruxolitinib and belumosudil is tolerable and induces responses despite treatment failure as monotherapies.
Caputo J, Peddireddi A, Bhatta S, Huang Y, Bezerra E, Brammer J, Larkin K, Mims A, Vasu S, Wall S, Choe H
Leuk Lymphoma
June 12, 2024Impact of chronic graft-versus-host disease on non-relapse mortality and survival.
Jiang J, Sigmund AM, Zhao Q, Elder P, Vasu S, Jaglowski S, Mims A, Choe H, Larkin K, Wall S, Grieselhuber N, William B, Penza S, Benson DM, Efebera YA, Sharma N
Leuk Lymphoma
March 23, 2024Post-infusion PD-1+CD8+CAR-T cells identify patients responsive to CD19-CAR-T therapy in non-Hodgkin's lymphoma.
Denlinger N, Song NJ, Zhang X, Jeon H, Peterson C, Wang Y, Reynolds K, Bolz R, Miao J, Song C, Wu D, Chan WK, Bezerra ED, Epperla N, Voorhees TJ, Brammer JE, Kittai AS, Bond DA, Sawalha Y, Sigmund AM, Reneau JC, Rubinstein MP, Hanel W, Christian B, Baiocchi RA, Maddocks KJ, Alinari L, Vasu S, de Lima M, Chung D, Jaglowski SM, Li Z, Huang X, Yang Y
Blood Adv
March 12, 2024Gilteritinib as Post-Transplant Maintenance for Acute Myeloid Leukemia With Internal Tandem Duplication Mutation of FLT3.
Levis MJ, Hamadani M, Logan B, Jones RJ, Singh AK, Litzow M, Wingard JR, Papadopoulos EB, Perl AE, Soiffer RJ, Ustun C, Ueda Oshima M, Uy GL, Waller EK, Vasu S, Solh M, Mishra A, Muffly L, Kim HJ, Mikesch JH, Najima Y, Onozawa M, Thomson K, Nagler A, Wei AH, Marcucci G, Geller NL, Hasabou N, Delgado D, Rosales M, Hill J, Gill SC, Nuthethi R, King D, Wittsack H, Mendizabal A, Devine SM, Horowitz MM, Chen YB, BMT-CTN 1506/MORPHO Study Investigators
J Clin Oncol
January 16, 2024A randomized phase 2 trial of oral vitamin A for graft-versus-host disease in children and young adults.
Khandelwal P, Langenberg L, Luebbering N, Lake K, Butcher A, Werling K, Ramos KN, Taggart C, Choe HK, Vasu S, Teusink-Cross A, Koo J, Wallace G, Romick-Rosendale L, Watanabe-Chailland M, Haslam DB, Lane A, Davies SM
Blood
September 22, 2023A novel CAR-T cell product targeting CD74 is an effective therapeutic approach in preclinical mantle cell lymphoma models.
Chan WK, Williams J, Sorathia K, Pray B, Abusaleh K, Bian Z, Sharma A, Hout I, Nishat S, Hanel W, Sloan SL, Yasin A, Denlinger N, Zhang X, Muthusamy N, Vasu S, de Lima M, Yang Y, Baiocchi R, Alinari L
Exp Hematol Oncol
September 4, 2023Phase 1 study of selinexor in combination with salvage chemotherapy in Adults with relapsed or refractory Acute myeloid leukemia.
Bhatnagar B, Zhao Q, Mims AS, Vasu S, Behbehani GK, Larkin K, Blachly JS, Badawi MA, Hill KL, Dzwigalski KR, Phelps MA, Blum W, Klisovic RB, Ruppert AS, Ranganathan P, Walker AR, Garzon R
Leuk Lymphoma
November 18, 2022North American Blastic Plasmacytoid Dendritic Cell Neoplasm Consortium: Position on Standards of Care and Areas of Need.
Pemmaraju N, Kantarjian HM, Sweet KL, Wang ES, Senapati J, Wilson NR, Konopleva MY, Frankel AE, Gupta V, Mesa RA, Ulrickson ML, Gorak E, Bhatia S, Budak-Alpdogan T, Mason JR, Garcia-Romero MT, Lopez-Santiago NC, Cesarman-Maus G, Vachhani P, Lee S, Bhatt VR, Blum W, Walter RB, Bixby D, Gojo I, Duvic M, Rampal RK, de Lima M, Foran JM, Fathi AT, Hall A, Jacoby MA, Lancet JE, Mannis GN, Stein AS, Mims AS, Rizzieri D, Olin RL, Perl AE, Schiller GJ, Shami PJ, Stone RM, Strickland S, Wieduwilt MJ, Daver NG, Ravandi F, Vasu S, Guzman ML, Roboz GJ, Khoury JD, Qazilbash MH, Aung P, Cuglievan B, Madanat YF, Kharfan-Dabaja MA, Pawlowska AB, Taylor J, Tallman MS, Dhakal P, Lane AA
Blood
November 14, 2022Longitudinal Survival Outcomes in Allogeneic Stem Cell Transplantation: An Institutional Experience.
Jiang J, Sigmund AM, Zhao Q, Elder P, Benson DM, Vasu S, Jaglowski S, Mims A, Choe H, Larkin K, Brammer JE, Wall S, Grieselhuber N, Saad A, Penza S, Efebera YA, Sharma N
Cancers (Basel)
October 22, 2022Bringing Patient and Caregivers Voices to the Clinical Trial Chorus: A Report from the BMT CTN Patient and Caregiver Advocacy Task Force.
Vasu S, Holtan SG, Shimamura A, Burnworth T, Whisenton S, Adams S, Nuechterlein B, Mortier N, Foster J, DiFronzo N, Horowitz M, Rizzo D, Foley A
Transplant Cell Ther
October 1, 2022AML-397 Integrated Safety Analysis of Tagraxofusp, a CD123-Directed Targeted Therapy, in Patients With Hematologic Malignancies.
Pammaraju N, Kantarjian H, Sweet K, Wang ES, Lane AA, Ali H, Stein AS, Yacoub A, Rizzieri D, Vasu S, Gupta V, Lee S, Schiller GJ, Foran JM, Taparia MS, Rosenblat TL, Walter RB, Sieminski D, Anant M, Patnaik MM, Mughal TI, Konopleva M
Clin Lymphoma Myeloma Leuk
October 1, 2022AML-465 Tagraxofusp, an Anti-CD123 Therapy, in Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm: Sub-Analysis of a Pivotal Trial by Age and Baseline Disease Involvement.
Pemmaraju N, Konopleva M, Sweet K, Stein A, Vasu S, Rizzieri D, Wang ES, Kantarjian H, Brooks C, Mughal T, Lane A
Clin Lymphoma Myeloma Leuk
October 1, 2022ABCL-509 Healthcare Utilization and Costs in Chimeric Antigen Receptor T-Cell Therapy for B-Cell Lymphoma.
Denlinger N, Huang Y, Braunstein Z, Sigmund A, Bajwa A, Kapoor N, Agyeman A, Fisher S, Purdin Z, Neal A, Yucebay F, Roddy J, Brammer J, William B, Saad A, Penza S, Voorhees T, Kittai A, de Lima M, Vasu S, Jaglowski S
Clin Lymphoma Myeloma Leuk
July 12, 2022Long-Term Benefits of Tagraxofusp for Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm.
Pemmaraju N, Sweet KL, Stein AS, Wang ES, Rizzieri DA, Vasu S, Rosenblat TL, Brooks CL, Habboubi N, Mughal TI, Kantarjian H, Konopleva M, Lane AA
J Clin Oncol
June 21, 2022Treatment patterns and outcomes of patients with CNS involvement of blastic plasmacytoid dendritic cell neoplasm (BPDCN).
Davis JA, Rizzieri DA, Lane AA, Taylor J, Faisal MS, Vasu S, Soong D, Li H, Herbst A, Greenwell IB
Leuk Lymphoma
May 1, 2022NCCN Guidelines® Insights: Hematopoietic Growth Factors, Version 1.2022.
Griffiths EA, Roy V, Alwan L, Bachiashvili K, Baird J, Cool R, Dinner S, Geyer M, Glaspy J, Gojo I, Hicks A, Kallam A, Kidwai WZ, Kloth DD, Kraut EH, Landsburg D, Lyman GH, Mahajan A, Miller R, Nachar V, Patel S, Patel S, Perez LE, Poust A, Riaz F, Rosovsky R, Rugo HS, Simon S, Vasu S, Wadleigh M, Westbrook K, Westervelt P, Berardi RA, Pluchino L
J Natl Compr Canc Netw
April 29, 2022Evaluation of allogeneic and autologous membrane-bound IL-21-expanded NK cells for chronic lymphocytic leukemia therapy.
Yano M, Sharpe C, Lance JR, Ravikrishnan J, Zapolnik K, Mo XM, Woyach JA, Sampath D, Kittai AS, Vasu S, Bhat SA, Rogers KA, Lee D, Muthusamy N, Byrd JC
Blood Adv
April 4, 2022Impact of Center Experience with Donor Type on Outcomes: A Secondary Analysis BMT CTN 1101Open for Accrual June 2012Open for Accrual June 2012.
Brunstein CG, O'Donnell PV, Logan B, Dawson P, Costa L, Cutler C, Craig M, Hogan W, M Horowitz M, Horwitz ME, Karanes C, Magenau JM, Malone A, McCarty J, McGuirk JP, Morris LE, Rezvani AR, Salit R, Vasu S, Eapen M, Fuchs EJ
Transplant Cell Ther
March 14, 2022Impact of diagnostic genetics on remission MRD and transplantation outcomes in older AML patients.
Murdock HM, Kim HT, Denlinger N, Vachhani P, Hambley BC, Manning BS, Gier S, Cho C, Tsai HK, McCurdy SR, Ho VT, Koreth J, Soiffer RJ, Ritz J, Carroll MP, Vasu S, Perales MA, Wang ES, Gondek LP, Devine SM, Alyea EP, Lindsley RC, Gibson CJ
Blood
March 3, 2022Assessment of Salvage Regimens Post CAR-T Cell Therapy for Patients with Diffuse Large B-Cell Lymphoma.
Sigmund AM, Denlinger N, Huang Y, Bond D, Voorhees T, Bajwa A, Elder P, Brammer JE, Saad A, Penza S, Vasu S, de Lima M, Jaglowski S, Kittai AS
Transplant Cell Ther
January 1, 2022Impact of Race and Geographic Area of Residence on Outcomes After Allogeneic Stem Cell Transplant.
Sigmund AM, Zhao Q, Jiang J, Elder P, Benson DM, Rosko A, Bumma N, Khan A, Devarakonda S, Vasu S, Jaglowski S, Mims A, Choe H, Larkin K, Brammer J, Wall S, Grieselhuber N, Saad A, Penza S, Efebera YA, Sharma N
Front Oncol
December 21, 2021Acute GVHD, BK hemorrhagic cystitis and age are risk factors for transplant-associated thrombotic microangiopathy in adults.
Vasu S, Bostic MG, Zhao Q, Sharma N, Puto M, Knight S, Scott D, Guzman R, Kromer M, Tackett K, Lind KE, Knill K, Watson E, Wall SA, Saad A, Choe HK, Larkin K, Brammer JE, Jaglowski SM, Penza S, Davies SM, Cataland SR
Blood Adv
December 2, 2021A phase I study of the fully human, fragment crystallizable-engineered, anti-CD-33 monoclonal antibody BI 836858 in patients with previously-treated acute myeloid leukemia.
Vasu S, Altman JK, Uy GL, Tallman MS, Gojo I, Lozanski G, Burkard U, Osswald A, James P, Rüter B, Blum W
Haematologica
December 2, 2021Randomized Phase III BMT CTN Trial of Calcineurin Inhibitor-Free Chronic Graft-Versus-Host Disease Interventions in Myeloablative Hematopoietic Cell Transplantation for Hematologic Malignancies.
Luznik L, Pasquini MC, Logan B, Soiffer RJ, Wu J, Devine SM, Geller N, Giralt S, Heslop HE, Horowitz MM, Jones RJ, Litzow MR, Mendizabal A, Muffly L, Nemecek ER, O'Donnell L, O'Reilly RJ, Palencia R, Schetelig J, Shune L, Solomon SR, Vasu S, Ho VT, Perales MA
J Clin Oncol
November 17, 2021PP2A is a therapeutically targetable driver of cell fate decisions via a c-Myc/p21 axis in Acute Myeloid Leukemia.
Goswami S, Mani R, Nunes J, Chiang CL, Zapolnik K, Hu EY, Frissora FW, Mo XM, Walker LA, Yan PS, Bundschuh R, Beaver L, Devine RD, Tsai YT, Ventura AM, Xie Z, Chen M, Lapalombella R, Walker AR, Mims AS, Larkin K, Grieselhuber NR, Bennett C, Phelps MA, Hertlein E, Behbehani GK, Vasu S, Byrd JC, Muthusamy N
Blood
October 28, 2021Diagnostic utility of bronchoscopy in newly diagnosed acute leukemia patients.
Koenig KL, Curley TP, Mani S, Keiter A, Zhao Q, Behbehani GK, Bhatnagar B, Blachly JS, Haque TZ, Larkin KTM, Long M, Mims AS, Vasu S, Wall SA, Byrd JC, Lustberg M, Walker AR, Grieselhuber NR
Hematol Oncol
October 22, 2021Acute cardiotoxicity after initiation of the novel tyrosine kinase inhibitor gilteritinib for acute myeloid leukemia.
Kim L, Fowler B, Campbell CM, Slivnick J, Nawaz H, Kaka Y, Ruz P, Vallakati A, Baliga R, Vasu S, Addison D
Cardiooncology
August 1, 2021Early toxicity and clinical outcomes after chimeric antigen receptor T-cell (CAR-T) therapy for lymphoma.
Brammer JE, Braunstein Z, Katapadi A, Porter K, Biersmith M, Guha A, Vasu S, Yildiz VO, Smith SA, Buck B, Haddad D, Gumina R, William BM, Penza S, Saad A, Denlinger N, Vallakati A, Baliga R, Benza R, Binkley P, Wei L, Mocarski M, Devine SM, Jaglowski S, Addison D
J Immunother Cancer
June 27, 2021Outcomes of Bone Marrow Compared to Peripheral Blood for Haploidentical Transplantation.
Sharma N, Faisal MS, Zhao Q, Jiang J, Elder P, Benson DM, Rosko A, Chaudhry M, Bumma N, Khan A, Devarakonda S, Vasu S, Jaglowski S, Mims AS, Choe H, Larkin K, Brammer JE, Wall S, Grieselhuber N, Saad A, Penza S, Sigmund AM, Efebera YA
J Clin Med
June 9, 2021Biologic Assignment Trial of Reduced-Intensity Hematopoietic Cell Transplantation Based on Donor Availability in Patients 50-75 Years of Age With Advanced Myelodysplastic Syndrome.
Nakamura R, Saber W, Martens MJ, Ramirez A, Scott B, Oran B, Leifer E, Tamari R, Mishra A, Maziarz RT, McGuirk J, Westervelt P, Vasu S, Patnaik M, Kamble R, Forman SJ, Sekeres MA, Appelbaum F, Mendizabal A, Logan B, Horowitz M, Cutler C
J Clin Oncol
April 1, 2021Discharge Disposition Following Hematopoietic Cell Transplantation: Predicting the Need for Rehabilitation and Association with Survival.
Wall SA, Zhao Q, Vasu S, Rosko A
Transplant Cell Ther
March 24, 2021Type of prior genotoxic insult determines the genomic characteristics of therapy-related myeloid neoplasms.
Ozga M, Blachly J, Eisfeld AK, Grieselhuber N, Larkin K, Walker A, Bhatnagar B, Behbehani G, Long M, Haque T, Vasu S, Zhao W, Jones D, Byrd JC, Mims AS, Saygin C
Am J Hematol
February 4, 2021Effect of Early Post-Transplantation Tacrolimus Concentration on the Risk of Acute Graft-Versus-Host Disease in Allogenic Stem Cell Transplantation.
Sharma N, Zhao Q, Ni B, Elder P, Puto M, Benson DM, Rosko A, Chaudhry M, Devarakonda S, Bumma N, Khan A, Vasu S, Jaglowski S, William BM, Mims A, Choe H, Larkin K, Brammer J, Wall S, Grieselhuber N, Saad A, Penza S, Efebera Y
Cancers (Basel)
November 24, 2020Comparison of fixed dose reduced-intensity conditioning with fludarabine and busulfan to PK-guided busulfan AUC (FluBu4K) in hematopoietic stem cell transplant for AML/MDS.
Rasor B, Dickerson T, Zhao Q, Elder P, Brammer JE, Larkin K, Jaglowski S, Mims A, Penza S, Vasu S, Wall SA, William B, Saad A, Roddy JVF, Choe H, Puto M
Leuk Lymphoma
October 13, 2020Clinical activity of axicabtagene ciloleucel in adult patients with Richter syndrome.
Kittai AS, Bond DA, William B, Saad A, Penza S, Efebera Y, Larkin K, Wall SA, Choe HK, Bhatnagar B, Vasu S, Brammer J, Shindiapina P, Long M, Mims A, O'Donnell L, Bhat SA, Rogers KA, Woyach JA, Byrd JC, Jaglowski SM
Blood Adv
October 8, 2020Safety of Axicabtagene Ciloleucel for the Treatment of Relapsed or Refractory Large B-Cell Lymphoma.
Grana A, Gut N, Williams K, Maakaron J, Porter K, William BM, Vasu S, Penza S, Brammer JE, Saad A, Puto M, Jaglowski SM, Roddy J
Clin Lymphoma Myeloma Leuk
September 4, 2020Incidence of venous thrombosis after peg-asparaginase in adolescent and young adults with acute lymphoblastic leukemia.
Underwood B, Zhao Q, Walker AR, Mims AS, Vasu S, Long M, Z Haque T, Blaser BW, Grieselhuber NR, Wall SA, Behbehani GK, Blachly JS, Larkin K, Byrd JC, Garzon R, Wang TF, Bhatnagar B
Int J Hematol Oncol
September 1, 2020Comparative analysis of antibiotic exposure association with clinical outcomes of chemotherapy versus immunotherapy across three tumour types.
Kulkarni AA, Ebadi M, Zhang S, Meybodi MA, Ali AM, DeFor T, Shanley R, Weisdorf D, Ryan C, Vasu S, Rashidi A, Patel MR
ESMO Open
August 10, 2020A phase I study of lenalidomide plus chemotherapy with idarubicin and cytarabine in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome.
Saygin C, Larkin K, Blachly JS, Orwick S, Ngankeu A, Gregory CT, Phelps MA, Mani S, Walker A, Garzon R, Vasu S, Walsh KJ, Bhatnagar B, Klisovic RB, Grever MR, Marcucci G, Byrd JC, Blum W, Mims AS
Am J Hematol
July 14, 2020Glasdegib as maintenance therapy for patients with AML and MDS patients at high risk for postallogeneic stem cell transplant relapse.
Kent A, Vasu S, Schatz D, Monson N, Devine S, Smith C, Gutman JA, Pollyea DA
Blood Adv
April 14, 2020Fc-engineered anti-CD33 monoclonal antibody potentiates cytotoxicity of membrane-bound interleukin-21 expanded natural killer cells in acute myeloid leukemia.
Mani R, Rajgolikar G, Nunes J, Zapolnik K, Wasmuth R, Mo X, Byrd JC, Lee DA, Muthusamy N, Vasu S
Cytotherapy
April 1, 2020Transfusion support for stem cell transplant recipients.
Adkins BD, Booth GS, Vasu S
Semin Hematol
February 1, 2020Selinexor in combination with decitabine in patients with acute myeloid leukemia: results from a phase 1 study.
Bhatnagar B, Zhao Q, Mims AS, Vasu S, Behbehani GK, Larkin K, Blachly JS, Blum W, Klisovic RB, Ruppert AS, Orwick S, Oakes C, Ranganathan P, Byrd JC, Walker AR, Garzon R
Leuk Lymphoma
February 1, 2020Outcomes of the cyclophosphamide, vincristine, prednisone (CVP) +/- rituximab (R-CVP) regimen in older patients with newly diagnosed Ph- acute lymphoblastic leukemia.
Saygin C, Grieselhuber N, Blachly J, Byrd JC, Vasu S, Larkin K, Behbehani G, Long M, Walker A, Bhatnagar B, Mims A
Leuk Res
Consulting and Related Relationships
More info forAt The Ohio State University Wexner Medical Center, we support a faculty member’s research and consulting in collaboration with medical device, research and/or drug companies because a faculty member’s expertise can guide important advancements in the practice of medicine and improve patient care. In order to provide effective management of these relationships, the university requires annual disclosures from all faculty members with external interests related to their university responsibilities. As of 09/30/2024, Dr. Vasu has reported no relationships with companies or entities.
Patient Comments
Dr. Vasu and her Care providers for oncology at The James are outstanding, very professional, and very caring. I think they really care about their patients and I've never had a bad experience in their care.
Dr. Vasu is very attentive and never rushes us.
Dr. Vasu is wonderful. She's not only concerned about my treatment but is aware of and remembers things happening in my personal life. She checks with me to make sure I'm doing well in every part of my life.
The Best
Dr Vasu and staff are the best! Knowledgeable, considerate, informative and professional.
Dr Vasu and team go above and beyond each time we are there. They have taken a difficult situation and made it manageable.
I always have plenty of time for questions to Dr Vasu & Kellie Lavoie, which I think is great.
Dr. Vasu and staff are wonderful. They have shown compassion for me and my family throughout my cancer treatment and follow up. I would recommend them to anyone who needs their services.